Navigation Links
Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
Date:5/19/2008

NEW YORK, May 19 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS), a biopharmaceutical company focused on development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease (AD), announced today that it has entered into a license agreement with Wyeth (NYSE: WYE) and Elan Pharma International Ltd. ("Elan") regarding certain of Intellect's patents and patent applications related to antibodies and methods of treatment for Alzheimer's disease. Under the terms of the agreement, Wyeth and Elan may pay Intellect potential future milestone payments and royalties based on sales of potential products, if it is determined that they are covered by patents that issue from Intellect's patent applications.

Dr. Chain, Intellect's Chairman and CEO and inventor of the licensed patents and patent applications, commented: "We are delighted to enter into this licensing agreement, which provides Intellect a share in the future success of potential Wyeth and Elan products while we continue to develop our proprietary monoclonal antibodies for the treatment of AD."

About Alzheimer's disease

Alzheimer's disease, the most common form of dementia, is characterized by progressive loss of memory and cognition, ultimately leading to complete debilitation and death. A hallmark feature of Alzheimer's pathology is the presence of insoluble protein deposits known as beta-amyloid on the surface of nerve cells, which results from the accumulation of soluble beta-amyloid in the brain. The effects of the disease are devastating to the patients as well as the caregivers, with significant associated health care costs. It is estimated that there are over 12 million people suffering from
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. IC Sciences Announces Launch of ICS Advisory Services Intellectual Property Platforms Available Through ICSciences Alliance
2. Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
3. Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimers Disease
4. Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School
5. ActivBiotics Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million
6. Amarin Secures Global Intellectual Property Rights for Lipid Programs
7. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
8. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
9. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
10. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
(Date:10/22/2014)... 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the ... steps for its Oral Amphotericin B program.  The ... in vitro work involving samples from HIV/AIDS ... to complete pre clinical studies and regulatory filings ... clinical trial, utilizing approximately $700,000 of funding and ...
(Date:10/22/2014)... DIEGO and HONG KONG ... innovative rare disease therapeutics enterprise, announced today that rare ... the company as vice president, research. Dr. McKew brings ... including key leadership positions at the National Institutes of ... its acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts ...
(Date:10/20/2014)... Convey Computer , the leader in hybrid-core ... University won first place in the 2014 MemoCODE ... team’s solution achieved the highest overall performance in the ... finisher. , Experts from all segments of the commercial ... using a variety of design tools, hardware and software. ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... SCOTTSDALE, Ariz., Sept. 17 MedTrust Online, a ... options for challenging patient cancer cases, has surpassed 5,000 ... Online also announced today that world-renowned oncologist Dr. Henry ... advisors. , , "5,000 users is ...
... ... children successfully take antiviral medications to fight the H1N1 and seasonal flu viruses. By ... medicine as prescribed. , ... MD, (PRWEB) September 17, 2009 -- As new cases of the H1N1 virus (swine flu) ...
... YM Enrolls First Patients in Multinational Randomized, Double-Blind Brain, ... Sept. 17 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: ... development company that identifies and advances a diverse portfolio ... today reported that nimotuzumab has been approved for marketing ...
Cached Biology Technology:MedTrust Online Surpasses 5,000 Registered Users and Adds Dr. Henry Friedman to Oncology Advisory Board 2FLAVORx Helps Families Fight Pandemic H1N1 Influenza Virus By Making Antiviral Medicine Taste Better 2FLAVORx Helps Families Fight Pandemic H1N1 Influenza Virus By Making Antiviral Medicine Taste Better 3FLAVORx Helps Families Fight Pandemic H1N1 Influenza Virus By Making Antiviral Medicine Taste Better 4YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 2YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 3YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 4
(Date:10/15/2014)... has admitted Johannes Gutenberg University Mainz (JGU) as ... hub continues to maintain a significant nationwide standing ... "The acceptance of Johannes Gutenberg University Mainz as ... milestone in the national and international competition for ... of Rhineland-Palatinate can be proud that Mainz University ...
(Date:10/15/2014)... , Oct. 15, 2014   Neurotechnology ... today announced the availability of the VeriLook ... Surveillance 3.0 provides real-time biometric face identification using ... digital surveillance cameras. The new version not only ... differentiates people from objects while they are moving ...
(Date:10/14/2014)... planet,s leading questions is how to produce enough food ... The Food and Agriculture Organization of the United Nations ... next 40 years to feed a growing global population, ... rise in food production. Plants—grains, cereals, fruits, vegetables, ... Current research must tap into our knowledge of ...
Breaking Biology News(10 mins):Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
... Do you want that in a pill or a shot? ... choice. The problem with administering many medications orally is that ... site in the gastrointestinal tract where the medicine can be ... by Brown University researchers could solve the problem by safely ...
... with common blood pressure medications may cause hypotension ... older patients, requiring hospitalization, according to a study ... Association Journal ) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj100702.pdf ... are among the most widely prescribed antibiotics, with ...
... Stanford University School of Medicine, in collaboration with BioParadox, ... plasma as a promising biologic treatment for myocardial infarction ... online in Cardiovascular Revascularization Medicine and will ... Therapy for Cardiovascular Disease at Columbia University Medical Center, ...
Cached Biology News:Magnetically controlled pill could boost body's absorption of drugs 2RevaTen platelet-rich plasma shows promise as potential treatment for heart attacks 2
APO-BrdU™ TUNEL Assay Kit *with Alexa Fluor® 488 anti-BrdU* *60 assays*...
...
IMAGEQUANT 300 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
RayBio Human Cytokine Antibody Array 1.1 (4 array membranes) with Accessory, detects 20 cytokines (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: